EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia

Xiaolan Li, Jingliao Zhang, Fang Liu, Tianfeng Liu, Ranran Zhang, Yumei Chen, Ye Guo, Yongjun Fang, Xiaojun Xu, Ching-Hon Pui, Xiaofan Zhu

Clinical Lymphoma Myeloma and Leukemia · 2023

DOI: 10.1016/j.clml.2023.04.012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023. Verfasst von Xiaolan Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Blood Diseases Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laborat…. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, St Jude Children's Research Hospital, American Lebanese Syrian Associated Charities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment outcomes for children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) remained poor despite the use of intensive chemotherapy, imatinib or dasatinib, and consolidative allogeneic hematopoietic cell transplantation. Oleverembatinib, a third-generation ABL inhibitor, was found to be highly effective and safe in adults with chronic myeloid leukemia and in some adults with relapsed or refractory Ph+ ALL. We reviewed the efficacy and safety profile of olverembatinib treatment in 6 children with relapsed Ph+ ALL and 1 with T-ALL and ABL class fusion, all of whom had previously received dasatinib or intolerance to dasatinib. The median duration of olverembatinib treatment was 70 days (range: 4-340) and the median cumulative dose was 600 mg (range: 80-3810). Complete remission with negative minimal residual level (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsPrecursor Cell Lymphoblastic Leukemia-LymphomaAdultHumansChildDasatinibPhiladelphia ChromosomeFusion Proteins, bcr-ablAlkynesBenzamidesPiperidinesPyrazolesPyridines

Stichwörter der Autor:innen

BCR::ABL1ChildHQP1351Tyrosine kinase inhibitor (TKI)

Substanzen

DasatinibProtein Kinase InhibitorsFusion Proteins, bcr-ablolverembatinibAlkynesBenzamidesPiperidinesPyrazolesPyridines

Autor:innen und Institutionen

  • Pediatric Blood Diseases Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospit…
  • Department of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China.
  • Division of Hematology/Oncology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Departments of Oncology, Global Pediatric Medicine and Pathology, St. Jude Children's Research Hospital, Memphis, TN. Electronic address: Ching-Hon.Pui@STJUDE.ORG.

Förderung

  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
  • St Jude Children's Research Hospital
  • American Lebanese Syrian Associated Charities
  • Ministry of Science and Technology of the People's Republic of China
  • National Natural Science Foundation of China

Zitieren

APA

Li, X., Zhang, J., Liu, F., Liu, T., Zhang, R., Chen, Y., Guo, Y., Fang, Y., Xu, X., Pui, C. H., & Zhu, X. (2023). Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.04.012

Vancouver

Li X, Zhang J, Liu F, Liu T, Zhang R, Chen Y, et al. Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2023. doi:10.1016/j.clml.2023.04.012

BibTeX
@article{Li2023,
  author = {Li, Xiaolan and Zhang, Jingliao and Liu, Fang and Liu, Tianfeng and Zhang, Ranran and Chen, Yumei and Guo, Ye and Fang, Yongjun and Xu, Xiaojun and Pui, Ching-Hon and Zhu, Xiaofan},
  title = {Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2023},
  doi = {10.1016/j.clml.2023.04.012}
}
Kostenlos starten →